New hope for tough stomach cancers: testing a powerful drug duo
NCT ID NCT07139587
Summary
This study is testing a new combination of two immunotherapy drugs (Iparomlimab/Tuvonralimab) with a chemotherapy drug for people with advanced stomach or gastroesophageal junction cancer. It's for patients whose cancer has continued to grow or who couldn't tolerate their first standard treatment. The main goals are to see if this combination can slow the cancer's progression, help patients live longer, and is safe to use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hebei General Hospital
Shijiazhuang, Hebei, 050000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.